Table 2. Effects of genistein on striatal, cortical and hippocampal TBARs and GSH levels and catalase activities in 3-NPA-treated ovariectomized rats.
| Groups | TBARs (nmol/g tissue) | GSH (μmol/ g tissue) | Catalase activity (U/g tissue) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Striatum | Cortex | Hippocampus | Striatum | Cortex | Hippocampus | Striatum | Cortex | Hippocampus | |
| Sham | 79±6 | 91.8±5 | 104±8 | 2.14±0.11 | 2.4±0.25 | 1.17±0.14 | 74.3±4.4 | 56.3±3.3 | 59.5±4.3 |
| Control | 115 x ±10 | 149 x ±7 | 156 x ±8 | 1.97±0.08 | 2.14±0.15 | 1.2±0.11 | 60.1±5.9 | 46.5±3.6 | 48.3±1.8 |
| 3-NPA | 173 x , * ±6 | 207* , x ±19 | 229* , x ±21 | 1.2* , x ±0.1 | 1.5* , x ±0.1 | 0.72* , x ±0.03 | 32.5 x , * ±3 | 31.5* , x ±1.9 | 26.7* , x ±2.7 |
| 17β-estradiol+ 3-NPA | 104 # ±5 | 130 # ±13 | 162 # ±4 | 1.6±0.15 | 2.06±0.24 | 1.33 # ±0.05 | 60.2 # ±3.8 | 55.6 # ±2.8 | 48.8 # ±2.3 |
| Genistein(10 mg/kg)+ 3-NPA | 106 # ±9 | 130 # ±9 | 100 # + ±5 | 1.81 # ±0.14 | 2±0.06 | 1.02±0.05 | 47.3±2.7 | 47 # ±2.6 | 57.3 # ±0.6 |
| Genistein(20 mg/kg)+ 3-NPA | 97 # ±5 | 129 # ±9 | 104 # + ±9 | 1.86 # ±0.11 | 1.9±0.16 | 1.15 # ±0.05 | 58.6 # ±3.2 | 51.1 # ±3.2 | 55.2 # ±2.1 |
| Genistein (20 mg/kg) | 89±8 | 94±6 | 107±5 | 2.01±0.13 | 2.19±0.2 | 1.11±0.1 | 66.2±4 | 49.3±4.3 | 56.1±1 |
3-NPA was administered i.p. (20 mg/kg) for 4 consecutive days. 17β-estradiol (2.5 mg/kg body weight, s.c) and genistein (10 and 20 mg/kg body weight, i.p) were administered for 8 days, beginning 4 days before and continued for 4 days one hour before 3-NPA injections. Data are presented as means ±S.E.M. (n = 6).
x statistically significant compared to sham group at P< 0.05
* statistically significant compared to control group at P< 0.05
# statistically significant from 3-NPA-treated group at P< 0.05
+ statistically significant compared to 17β-estradiol-pretreated group at P< 0.05 (One-way ANOVA followed by Tukey test).